Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Medical Oncology · Invasive Ductal Carcinoma of the Breast

Staging and Advanced Risk Stratification

At a Glance

Breast cancer stage reflects both where the cancer is and how its biology behaves, including grade and ER, PR, and HER2 status. For eligible early hormone receptor-positive, HER2-negative cancers, Oncotype DX and MammaPrint help estimate whether chemotherapy is likely to add benefit.

Determining the “stage” of your breast cancer is a process that has evolved significantly. In the past, doctors looked almost exclusively at the size of the tumor and whether it had spread. Today, your stage also includes the “personality” of the cancer—its grade and biomarker status—to give a much more accurate picture of your outlook and treatment needs [1][2].

Anatomic vs. Prognostic Staging

The American Joint Committee on Cancer (AJCC) 8th edition is the current reference framework. It uses two different “lenses” to look at your diagnosis [3]:

  • Anatomic Staging: This uses the traditional TNM system. T describes the tumor size and any local invasion of the skin or chest wall, N describes whether cancer is in the lymph nodes, and M describes metastasis (spread to distant organs) [1][4].
  • Prognostic Staging: This is the modern approach. It takes the TNM information and adds your cancer’s “biology”: the Nottingham grade, ER/PR status, and HER2 status [1][5].

Because biology is so powerful, your prognostic stage may be different from your anatomic stage. For example, a large tumor with very favorable biology (like a Grade 1, ER-positive cancer) may be “downstaged” to a lower prognostic stage. Conversely, a small tumor with aggressive features (like Triple-Negative or HER2-positive) might be “upstaged” because it requires more intensive management [5][6]. Note that prognostic stage often provides better survival stratification, but does not completely replace anatomic stage.

Clinical vs. Pathologic Staging

You may see the letters “c” or “p” before your stage (e.g., cT2N0 or pT1N0). These indicate when the staging was determined [2][7]:

  • Clinical Staging ©: Based on what the doctor can see and feel during a physical exam and what is visible on imaging (like mammograms or MRIs) before any treatment begins [2].
  • Pathologic Staging (p): Based on the actual examination of the tissue removed during surgery. This is generally the most accurate “final” stage [2][8].
  • Post-Neoadjuvant Staging (yp): If you receive chemotherapy or hormone therapy before surgery (neoadjuvant therapy), your final pathology report will use the prefix “yp” to show how the residual disease responded to that treatment. This describes the residual cancer and does not erase the pretreatment clinical extent [9][8].

Genomic Risk Stratification: Beyond the Microscope

For many patients with HR-positive, HER2-negative early-stage breast cancer, doctors use genomic tests to see if chemotherapy will actually help. These tests look at the activity of specific genes within your tumor to predict the risk of the cancer returning [10][11].

Oncotype DX (21-Gene Recurrence Score)

The Oncotype DX test provides a Recurrence Score (RS) from 0 to 100. It is used to decide if chemotherapy should be added to hormone therapy, but its interpretation depends heavily on tumor size, nodal stage, and menopausal status [12][13].

  • RS 0–10 (equivalently, <11): Under AJCC 8th-edition rules, T1-T2 N0 ER-positive/HER2-negative tumors with this score are assigned to pathologic prognostic stage IA, regardless of grade.
  • RS 11–25: This is a “shared-decision zone.”
    • If you are over age 50 and node-negative: Research (the TAILORx trial) shows chemotherapy usually provides no extra benefit [12][14].
    • If you are age 50 or younger and node-negative: There may be a small benefit from chemotherapy for scores in the 16–25 range, though this may partly reflect ovarian suppression rather than direct cytotoxic effects [12][14].
  • RS 26 and above: The risk of recurrence is higher, and chemotherapy is typically recommended to reduce that risk [15][14].
  • Note on Lymph Nodes (1 to 3 positive nodes): In the RxPONDER trial, postmenopausal patients with an RS of 0-25 were able to omit chemotherapy safely. In premenopausal patients with 1-3 positive nodes, benefit is often seen from chemotherapy, though again, the effect of ovarian suppression is a significant factor in discussions [16][11].

MammaPrint (70-Gene Signature)

MammaPrint categorizes tumors as either “Low Risk” or “High Risk.” It is often used when a tumor has features that make its behavior hard to predict [17][18].

  • Clinical High/Genomic Low: If your tumor looks aggressive on paper (clinical high risk) but the MammaPrint score is “Low Risk,” your care team will weigh the clinical risk, nodal status, and your preferences when considering whether chemotherapy provides a meaningful absolute benefit [17][19].

Important Limitations

These genomic tests are not for everyone. They are specifically validated for HR-positive, HER2-negative cancers [10]. They are currently not recommended for:

  • Triple-Negative Breast Cancer [10].
  • HER2-Positive Breast Cancer [10].
  • Advanced Regional or Metastatic Cancer (such as cancer that has already spread to 4 or more regional lymph nodes or distant organs) [10][20].

In these cases, the decision for chemotherapy is based on the standard prognostic stage and other clinical factors rather than a genomic score [20][10].

Common questions in this guide

Why can my anatomic and prognostic breast cancer stages be different?
Anatomic stage describes tumor size or local invasion, lymph-node involvement, and distant spread. Prognostic stage adds tumor grade and ER, PR, and HER2 results, so favorable biology can lower the prognostic stage while aggressive biology can raise it.
What do the c, p, and yp prefixes mean in breast cancer staging?
The c prefix means the stage was estimated from examination and imaging before treatment, while p means it was based on tissue removed during surgery. The yp prefix is used after treatment given before surgery and describes the cancer that remains in the surgical specimen; it does not erase the original clinical extent.
Who is usually eligible for Oncotype DX or MammaPrint testing?
These tests are mainly validated for selected early-stage, hormone receptor-positive, HER2-negative breast cancers. They are generally not recommended for triple-negative or HER2-positive disease, advanced regional disease such as four or more involved regional lymph nodes, or metastatic cancer.
How does an Oncotype DX score affect chemotherapy decisions?
An Oncotype DX score of 0–10 generally indicates low genomic risk, while a score of 26 or higher usually supports adding chemotherapy in appropriate early-stage patients. Scores of 11–25 are interpreted with tumor size, lymph-node status, age, and menopausal status, and the test helps estimate chemotherapy benefit rather than replacing hormone therapy.
Does age or menopause change how an Oncotype DX score is interpreted?
For node-negative disease, people over 50 with a score of 11–25 usually receive no additional chemotherapy benefit, while some people age 50 or younger may have a small benefit at scores of 16–25. For one to three positive nodes, postmenopausal people with scores of 0–25 may be able to omit chemotherapy, whereas premenopausal people often discuss a chemotherapy benefit that may partly reflect ovarian suppression.
Does a low-risk MammaPrint result mean chemotherapy is unnecessary?
A low-risk MammaPrint result does not automatically mean chemotherapy is unnecessary. If clinical features suggest higher risk, the care team also considers tumor size, lymph-node status, overall biology, and your preferences when estimating the likely absolute benefit.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my 'Prognostic Stage' different from my 'Anatomic Stage,' and what does that tell us about my cancer's biology?
  2. 2.Based on my ER, PR, and HER2 results, am I a candidate for genomic testing like Oncotype DX or MammaPrint?
  3. 3.How does my age or menopausal status change the way we interpret my Oncotype DX or MammaPrint score?
  4. 4.If my Oncotype DX score is in the 'intermediate' range, what specific factors will we use to decide if chemotherapy is right for me?
  5. 5.For my specific stage and biology, do current guidelines (like NCCN or ASCO) recommend adding chemotherapy to my hormone treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.

    Weiss A, King TA, Hunt KK, Mittendorf EA

    The Surgical clinics of North America 2018; (98(4)):687-702 doi:10.1016/j.suc.2018.03.005.

    PMID: 30005768
  2. 2

    Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution.

    Aldrees R, Gao X, Zhang K, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2021; (34(2)):291-299 doi:10.1038/s41379-020-00650-4.

    PMID: 32778677
  3. 3

    Anatomy and Breast Cancer Staging: Is It Still Relevant?

    Plichta JK, Campbell BM, Mittendorf EA, Hwang ES

    Surgical oncology clinics of North America 2018; (27(1)):51-67 doi:10.1016/j.soc.2017.07.010.

    PMID: 29132565
  4. 4

    Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual, 8th Edition, and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging.

    Teichgraeber DC, Guirguis MS, Whitman GJ

    AJR. American journal of roentgenology 2021; (217(2)):278-290 doi:10.2214/AJR.20.25223.

    PMID: 33594908
  5. 5

    Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.

    Wang M, Chen H, Wu K, et al.

    Breast (Edinburgh, Scotland) 2018; (37()):56-63 doi:10.1016/j.breast.2017.10.011.

    PMID: 29100045
  6. 6

    Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer.

    Seow YH, Wong RX, Lim JHC, et al.

    Journal of breast cancer 2019; (22(2)):260-273 doi:10.4048/jbc.2019.22.e16.

    PMID: 31281728
  7. 7

    Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage.

    Koh J, Kim MJ

    Korean journal of radiology 2019; (20(1)):69-82 doi:10.3348/kjr.2018.0231.

    PMID: 30627023
  8. 8

    Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.

    Kantor O, Laws A, Pastorello RG, et al.

    Annals of surgical oncology 2021; (28(12)):7347-7355 doi:10.1245/s10434-021-09951-7.

    PMID: 33956276
  9. 9

    Novel Postneoadjuvant Prognostic Breast Cancer Staging System.

    Winchester DJ, Singh L, Edge SB, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(17)):1948-1960 doi:10.1200/JCO-24-01739.

    PMID: 40215445
  10. 10

    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.

    Andre F, Ismaila N, Allison KH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(16)):1816-1837 doi:10.1200/JCO.22.00069.

    PMID: 35439025
  11. 11

    Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.

    Sparano JA, Crager M, Gray RJ, et al.

    NEJM evidence 2024; (3(8)):EVIDoa2300267 doi:10.1056/EVIDoa2300267.

    PMID: 39041867
  12. 12

    Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

    Sparano JA, Gray RJ, Makower DF, et al.

    The New England journal of medicine 2018; (379(2)):111-121 doi:10.1056/NEJMoa1804710.

    PMID: 29860917
  13. 13

    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

    Andre F, Ismaila N, Henry NL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(22)):1956-1964 doi:10.1200/JCO.19.00945.

    PMID: 31150316
  14. 14

    Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.

    Henry NL, Somerfield MR, Abramson VG, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(22)):1965-1977 doi:10.1200/JCO.19.00948.

    PMID: 31206315
  15. 15

    21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.

    Geyer CE, Tang G, Mamounas EP, et al.

    NPJ breast cancer 2018; (4()):37 doi:10.1038/s41523-018-0090-6.

    PMID: 30456299
  16. 16

    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

    Kalinsky K, Barlow WE, Gralow JR, et al.

    The New England journal of medicine 2021; (385(25)):2336-2347 doi:10.1056/NEJMoa2108873.

    PMID: 34914339
  17. 17

    70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

    Piccart M, van 't Veer LJ, Poncet C, et al.

    The Lancet. Oncology 2021; (22(4)):476-488 doi:10.1016/S1470-2045(21)00007-3.

    PMID: 33721561
  18. 18

    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

    Cardoso F, van't Veer LJ, Bogaerts J, et al.

    The New England journal of medicine 2016; (375(8)):717-29 doi:10.1056/NEJMoa1602253.

    PMID: 27557300
  19. 19

    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

    Krop I, Ismaila N, Andre F, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(24)):2838-2847 doi:10.1200/JCO.2017.74.0472.

    PMID: 28692382
  20. 20

    Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.

    Cooper K, Nalbant G, Essat M, et al.

    Breast cancer research and treatment 2025; (210(2)):229-247 doi:10.1007/s10549-024-07596-0.

    PMID: 39899163

This page is for informational purposes only and does not constitute medical advice. Your breast cancer team should interpret your stage, biomarker results, and genomic score in the context of your health and treatment goals.

Get notified when new evidence is published on breast ductal adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.